Gilteritinib: Repurposing of AXL‐targeting kinase inhibitors against COVID‐19

Chen, Yisa; Xue, Yiying; Yang, Jing

doi:10.1002/jmv.28592

Cited by 3 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These pressures can influence the survival and replication of viral strains, with some variants becoming more successful due to their specific adaptations. The selection pressure drives the process of natural selection, which can result in the emergence of new viral strains with improved fitness in a given environment [ 56 , 57 , 58 , 59 ]. Therefore, the selective pressure on CaChPV and FeChPV warrants attention, and further monitoring of the virus should be intensified to assess its evolutionary status.…”

Section: Discussionmentioning

confidence: 99%

Phylogenetic Analysis and Codon Usage Bias Reveal the Base of Feline and Canine Chaphamaparvovirus for Cross-Species Transmission

Zhang

Pan

et al. 2023

Animals

View full text Add to dashboard Cite

Chaphamaparvoviruses (ChPVs) are ancient viruses that have been detected in a variety of hosts. In this study, through a phylogenetic analysis and the adaptability of ChPV to multiple hosts, we evaluated the basis for the ability of feline (FeChPV) and canine ChPV (CaChPV) for cross-species transmission. Phylogenetic analysis showed that FeChPV and CaChPV were closely related. Notably, two strains of ChPVs isolated from domestic cats and two from dogs clustered together with CaChPVs and FeChPVs, respectively, suggesting that the stringent boundaries between canine and feline ChPV may be broken. Further analysis revealed that CaChPV and FeChPV were more adapted to dogs than to cats. Mutation analysis identified several shared mutations in cross-species-transmissible strains. Furthermore, the VP structures of FeChPV and CaChPV exhibited a high degree of similarity across both cross-species-transmissible and non-cross-species-transmissible strains. However, it is crucial to note that these results are largely computational, and limitations exist in terms of the number and diversity of samples analyzed; the capacity for cross-species transmission should be approached with caution and elucidated in further studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Phylogenetic Analysis and Codon Usage Bias Reveal the Base of Feline and Canine Chaphamaparvovirus for Cross-Species Transmission

Zhang

Pan

et al. 2023

Animals

View full text Add to dashboard Cite

show abstract

“…In addition, there are inhibitors that target other receptors of SARS-CoV-2. For instance, gilteritinib and nintedanib specifically target the AXL receptor, while imatinib targets AXL-related proteins ( Chen et al., 2023c ). Host protease inhibitors also play a crucial role in host-targeted antiviral therapy.…”

Section: Treatments Targeting Host Factorsmentioning

confidence: 99%

Host factors of SARS-CoV-2 in infection, pathogenesis, and long-term effects

Zhang,

Chen,

Tian

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

SARS-CoV-2 is the causative virus of the devastating COVID-19 pandemic that results in an unparalleled global health and economic crisis. Despite unprecedented scientific efforts and therapeutic interventions, the fight against COVID-19 continues as the rapid emergence of different SARS-CoV-2 variants of concern and the increasing challenge of long COVID-19, raising a vast demand to understand the pathomechanisms of COVID-19 and its long-term sequelae and develop therapeutic strategies beyond the virus per se. Notably, in addition to the virus itself, the replication cycle of SARS-CoV-2 and clinical severity of COVID-19 is also governed by host factors. In this review, we therefore comprehensively overview the replication cycle and pathogenesis of SARS-CoV-2 from the perspective of host factors and host-virus interactions. We sequentially outline the pathological implications of molecular interactions between host factors and SARS-CoV-2 in multi-organ and multi-system long COVID-19, and summarize current therapeutic strategies and agents targeting host factors for treating these diseases. This knowledge would be key for the identification of new pathophysiological aspects and mechanisms, and the development of actionable therapeutic targets and strategies for tackling COVID-19 and its sequelae.

show abstract

Safety Profile of Paxlovid in the Treatment of COVID-19

Lv,

Gao,

Zeng

et al. 2024

CPD

View full text Add to dashboard Cite

Background:: With the urgent and widespread application of Paxlovid, a novel antiviral drug for Coronavirus Disease 2019 (COVID-19) in clinical practice, concerns regarding its actual efficacy and safety have emerged. In order to provide more evidence to support its clinical application, we sought to perform a descriptive analysis of cases who experienced at least one Paxlovid-related adverse event (AEs) and reported to the FDA Adverse Event Reporting System (FAERS) in the post-marketing period. Methods:: Individual adverse event reports between January 1, 2022 and September 30, 2022, were downloaded from the FAERS website. We completed a descriptive study about the safety of Paxlovid in the treatment of COVID-19. Further, we also analyzed the onset time of Paxlovid-related AEs Results:: As of 30 September 2022, 16,529 de-duplicated cases were submitted to the FDA, and 5,860 (35.45%) were female. The average age was 58.38 years (S.D. 15.50). Most reports (12,390, 74.96%) were submitted by consumers and 1,436 (8.68%) concerned serious outcomes. The most frequently reported AEs were disease recurrence (7,724, 16.23%), dysgeusia (2,877, 6.05%), and diarrhoea (1,448, 3.04%). The median onset time of Paxlovid-related AEs was 8 days (interquartile range,1-10 days), and most of the cases (2,629, 19.12%) occurred on the day after Paxlovid initiation. Conclusion:: This study indicates that the most common AEs reported with Paxlovid in post-marketing experience are consistent with the safety assessment of antiviral drugs. Even without emerging apparent safety concerns, the incidence of serious outcomes was unexpectedly high, and a few cases of potential new AEs occurred.

show abstract

Gilteritinib: Repurposing of AXL‐targeting kinase inhibitors against COVID‐19

Cited by 3 publications

References 14 publications

Phylogenetic Analysis and Codon Usage Bias Reveal the Base of Feline and Canine Chaphamaparvovirus for Cross-Species Transmission

Phylogenetic Analysis and Codon Usage Bias Reveal the Base of Feline and Canine Chaphamaparvovirus for Cross-Species Transmission

Host factors of SARS-CoV-2 in infection, pathogenesis, and long-term effects

Safety Profile of Paxlovid in the Treatment of COVID-19

Contact Info

Product

Resources

About